Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irbesartan and Amlodipine Tablets vs Irbesartan in Primary Hypertension
CTR20222997Phase 3Completed
- Sponsor
- Hunan Huize Biopharmaceutical Technology
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of irbesartan + amlodipine in essential hypertension (3 arms), sponsored by Hunan Huize Biopharmaceutical Technology. Primary endpoint: Change in seated diastolic blood pressure at 8 weeks. Started Nov 2022; status: completed.
02
Drugs
irbesartan + amlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20222997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222997.